email article
All adenoviral vector vaccine platforms are not the same, and the Johnson & Johnson COVID-19 vaccine may have different biologic characteristics and biologic effects than the AstraZeneca vaccine, researchers from Johnson & Johnson s Janssen unit argued.
In a letter to the
New England Journal of Medicine published Friday, Macaya Douoguih, MD, of Janssen Vaccines and Prevention in the Netherlands, and colleagues responded to a case report on one of the six U.S. cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia associated with the vaccine, published in
NEJM on Wednesday.
Not surprisingly, Douoguih s group asserted the cases were insufficient evidence of a causal relationship between the J&J vaccine and CVST with thrombocytopenia, claiming the rate occurs within the expected background rate for this extremely rare event. However, they went further, attempting to distance their adverse events from those associated with AstraZeneca s vacc